Design Therapeutics closed at $10.63 on Nov 4, up 2.80%, 33.3% below its 52-week closing high. Volume of 315.6K shares was 0.71× its 20-day average (below normal).
Split-adjusted performance: -11.2% over one month, -26.9% over six months, +62.3% over one year.
Short interest was 6.7M shares at the Oct 15 settlement (21.8% of float, 12.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| DSGNDesign Therapeutics | $10.63 | +2.80% | −26.9% | — | — | — | $665.2M | |
| AVBPArriVent BioPharma | $13.49 | +3.61% | −54.5% | — | — | — | $665.2M | Compare |
| ZVRAZevra Therapeutics | $11.17 | +8.87% | −0.7% | +44.9% | 48.8% | 8.6 | $663.3M | Compare |
| IMMXImmix Biopharma | $7.97 | +3.37% | −22.8% | — | — | — | $660.7M | Compare |
| OLMAOlema Pharmaceuticals | $7.54 | +2.58% | −50.4% | — | — | — | $659.7M | Compare |
| LXRXLexicon Pharmaceuticals | $1.48 | +1.37% | −7.5% | −97.6% | −4591.8% | — | $658.5M | Compare |
| KURAKura Oncology | $7.61 | −22.98% | −20.4% | +36.5% | −327.3% | — | $677.0M | Compare |
| OBXObsidian Therapeutics | $10.99 | −16.93% | — | — | — | — | $678.9M | Compare |
| GERNGeron | $1.08 | +16.13% | −31.6% | +17.2% | −29.0% | — | $693.9M | Compare |
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
